These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Physical compatibility of cisatracurium with selected drugs during simulated Y-site administration. Foushee JA; Fox LM; Gormley LR; Lineberger MS Am J Health Syst Pharm; 2015 Mar; 72(6):483-6. PubMed ID: 25736944 [TBL] [Abstract][Full Text] [Related]
3. Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration. Holyk AA; Lindner AH; Lindner SE; Shippert BW Am J Health Syst Pharm; 2022 Jan; 79(1):e27-e33. PubMed ID: 34390244 [TBL] [Abstract][Full Text] [Related]
4. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Ruiz VH; Shen Y; Abouelhassan Y; Fouad A; Nicolau DP; Kuti JL Am J Health Syst Pharm; 2024 Jan; 81(1):e21-e29. PubMed ID: 37740370 [TBL] [Abstract][Full Text] [Related]
5. Assessment of the physical compatibility of injectable enrofloxacin with commonly used intravenous fluids and drugs during simulated Y-port administration. Aghili A; Thomovsky EJ; Johnson PA; Brooks AC; Pierce TJ; Gochenauer AE Am J Vet Res; 2021 May; 82(5):358-366. PubMed ID: 33904804 [TBL] [Abstract][Full Text] [Related]
6. Physical compatibility of ceftolozane-tazobactam with selected i.v. drugs during simulated Y-site administration. Thabit AK; Hamada Y; Nicolau DP Am J Health Syst Pharm; 2017 Jan; 74(1):e47-e54. PubMed ID: 28007721 [TBL] [Abstract][Full Text] [Related]
7. Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients. Foushee JA; Meredith P; Fox LM; Wilder AG Am J Health Syst Pharm; 2020 Jul; 77(14):1144-1148. PubMed ID: 32537625 [TBL] [Abstract][Full Text] [Related]
8. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Singh BN; Dedhiya MG; DiNunzio J; Chan P; Kupiec TC; Trissel LA; Laudano JB Am J Health Syst Pharm; 2011 Nov; 68(22):2163-9. PubMed ID: 22058102 [TBL] [Abstract][Full Text] [Related]
9. Nefopam hydrochloride compatibility and stability with selected proton pump inhibitors in bionolyte G5 injection for intravenous infusion. Kambia NK; Luyckx M; Dine T; Dupin-Spriet T; Gressier B; Brunet C J Clin Pharm Ther; 2009 Feb; 34(1):25-31. PubMed ID: 19125900 [TBL] [Abstract][Full Text] [Related]
10. Intravenous Compatibility of Ceftazidime-Avibactam and Aztreonam Using Simulated and Actual Y-site Administration. O'Donnell JN; Xu A; Lodise TP Clin Ther; 2020 Aug; 42(8):1580-1586.e2. PubMed ID: 32684326 [TBL] [Abstract][Full Text] [Related]
11. Physical compatibility of tedizolid phosphate with selected i.v. drugs during simulated Y-site administration. Ghazi I; Hamada Y; Nicolau DP Am J Health Syst Pharm; 2016 Nov; 73(21):1769-1776. PubMed ID: 27769972 [TBL] [Abstract][Full Text] [Related]
12. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. De Basagoiti A; Katsumiti A; Abascal S; Bustinza A; López-Giménez LR; Pascual P; De Miguel M; Campino A Eur J Pediatr; 2021 Apr; 180(4):1169-1176. PubMed ID: 33128625 [TBL] [Abstract][Full Text] [Related]
13. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Trissel LA; Martinez JF Am J Hosp Pharm; 1994 Feb; 51(4):495-9. PubMed ID: 8017415 [TBL] [Abstract][Full Text] [Related]
14. Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures. Foushee JA; Meredith P; Fox LM; Grace E Int J Pharm Compd; 2016; 20(4):328-332. PubMed ID: 28333677 [TBL] [Abstract][Full Text] [Related]
15. Physical compatibility of Xuebijing injection with 53 intravenous drugs during simulated Y-site administration. Tong T; Li P; Ding H; Huang Y; Liu S PLoS One; 2024; 19(3):e0299694. PubMed ID: 38517862 [TBL] [Abstract][Full Text] [Related]
16. Compatibility of verapamil hydrochloride with penicillin admixtures during simulated Y-site injection. Thompson DF; Stiles ML; Allen LV; Tu YH Am J Hosp Pharm; 1988 Jan; 45(1):142-5. PubMed ID: 3348228 [TBL] [Abstract][Full Text] [Related]
17. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Lu J; Liu Q; Kupiec TC; Vail H; Lynch LR; Fam DS; Vu NT Int J Pharm Compd; 2021; 25(1):52-61. PubMed ID: 33503010 [TBL] [Abstract][Full Text] [Related]
18. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Asempa TE; Avery LM; Kidd JM; Kuti JL; Nicolau DP Am J Health Syst Pharm; 2018 Jul; 75(14):1048-1056. PubMed ID: 29895521 [TBL] [Abstract][Full Text] [Related]
19. Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in Water. Meyer K; Santarossa M; Danziger LH; Wenzler E Hosp Pharm; 2017 Mar; 52(3):221-228. PubMed ID: 28439137 [No Abstract] [Full Text] [Related]
20. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Avery LM; Chen IH; Reyes S; Nicolau DP; Kuti JL Clin Ther; 2019 Oct; 41(10):2162-2170. PubMed ID: 31506218 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]